Drug intelligence / Profile preview

AGN-241622

Development stage: Discontinued
Lead developer: Allergan
Modality: Small Molecules
Administration: Ophthalmic

Overview

AGN-241622 is a small molecule ophthalmic drug developed for the treatment of presbyopia. It acts as an alpha-2 adrenergic receptor agonist, targeting the ADRA2 (alpha-2 adrenergic receptor) to induce miosis and prevent pupil dilation, thereby improving near vision in patients with presbyopia. The drug was initially developed by Allergan and later became part of AbbVie's portfolio following acquisition. Clinical development reached Phase 1/2 trials but was terminated before approval[1][2][3][4][5]. The primary indication investigated was presbyopia.

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on AGN-241622.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGN-241622.

Explore the full profile